Fulcrum Therapeutics (NASDAQ: FULC)
Fulcrum Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Fulcrum Therapeutics Company Info
Fulcrum Therapeutics, Inc. is a clinical stage biopharmaceutical company. The firm develops new medicines and focuses on unlocking gene control mechanisms to develop small molecule therapies. Its product candidate includes Losmapimod and FTX-HbF. The company was founded by Michael R. Green, Danny Reinberg, Rudolf Jaenisch, Jeannie T. Lee, and Bradley E. Bernstein on August 18, 2015 and is headquartered in Cambridge, MA.
News & Analysis
2 Soaring Biotech Stocks With More Fuel in the Tank
These recent winners still have a long way to run.
Why Fulcrum Therapeutics Popped Again on Tuesday
Compelling clinical-trial data that could validate the company's unique approach to new drug development inspired a slew of analyst upgrades.
Valuation
Earnings Transcripts
Fulcrum Therapeutics, Inc. (FULC) Q1 2020 Earnings Call Transcript
FULC earnings call for the period ending March 31, 2020.
Fulcrum Therapeutics, Inc. (FULC) Q4 2019 Earnings Call Transcript
FULC earnings call for the period ending December 31, 2019.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.